Group 1 - The report highlights that as of June 8, 2025, the Beijing Stock Exchange (BSE) has accepted 98 companies, covering various sectors including high-end equipment manufacturing, TMT, chemical new materials, consumption, and biomedicine [3][12][13] - The focus is on selecting "back-up troops" from the new productivity sector, particularly those in intelligent connected new energy vehicles, hydrogen energy, new materials, innovative drugs, and commercial aerospace [3][4] - The report identifies six key companies: Yatu High-tech, Yuelong Technology, Daya Co., Yongli Precision, Haiseng Medical, and Haode CNC, which are recognized as national-level specialized and innovative "little giant" enterprises [5][23] Group 2 - Yatu High-tech specializes in high-performance industrial coatings, with a projected revenue of 742 million yuan and a net profit of 149 million yuan for 2024, reflecting a year-on-year revenue growth of 16.68% [28][34] - Yuelong Technology focuses on flexible pipelines for fluid transport, expecting a revenue of 262 million yuan and a net profit of 84 million yuan in 2024, with a revenue growth of 19.62% [5][24] - Daya Co. is a leader in metal surface treatment, with a projected revenue of 1.199 billion yuan and a net profit of 150.93 million yuan for 2024, showing a revenue increase of 23.86% [6][24] - Yongli Precision specializes in automotive shock absorber components, anticipating a revenue of 568 million yuan and a net profit of 94.81 million yuan in 2024, with a revenue growth of 11.72% [6][24] - Haiseng Medical produces anesthesia and monitoring medical devices, with expected revenue of 304 million yuan and a net profit of 70.92 million yuan for 2024, indicating a slight decline in revenue [6][24] - Haode CNC is recognized for its machinery used in panel furniture production, with a projected revenue of 458 million yuan and a net profit of 66.69 million yuan in 2024, reflecting a decrease in revenue [6][24]

瑞财经 王敏 5月29日，北交所官网显示，浙江海圣医疗器械股份有限公司（以下简称：海圣医疗）IPO申请获受理，保荐机构为中信证 券，保荐代表人为蔡斌、董超，会计师事务所为天健。 招股书这是，海圣医疗是面向全球的麻醉、监护类医疗器械综合产品提供商，主营业务为麻醉、监护类医疗器械产品的研发、生产和 销售，产品已广泛应用于麻醉科、ICU病房、急诊科等科室的终端临床需求。 业绩方面，2022年至2024年（报告期内），海圣医疗营业收入分别为2.68亿元、3.06亿元和3.04亿元；净利润分别为7011.04万元、 7803.67万元和7091.75万元。 2024年，海圣医疗营收、净利双降。其中，营业收入同比下降了0.65%，净利润同比下降了9.12%。 根据审阅报告，截至2025年3月末，公司资产总额为4.92亿元，较上年末下降0.82%；归属于母公司所有者权益为4.23亿元，较上年末增 加2.93%。 2025年1-3月，公司实现营业收入6361.79万元，较上年同期增加21.62%；归属于母公司股东的净利润为1183.53万元，较上年同期增加 23.25%。 海圣医疗已建成遍布国内绝大多数省市地区的销售网络，主 ...

Group 1: IPO Applications - Beijing Stock Exchange accepted three IPO applications on May 29, 2025: Dalian Meidele (874489), Zhejiang Yongli Precision (874457), and Zhejiang Haiseng Medical (873794) [1] - As of now, a total of 12 companies have submitted IPO applications to the Beijing Stock Exchange in 2025 [1] Group 2: Dalian Meidele Industrial Automation Co., Ltd. - Dalian Meidele is a national high-tech enterprise specializing in the research, design, manufacturing, and sales of intelligent manufacturing equipment, primarily modular conveyor systems and industrial components [4] - The company has a registered capital of 56.123 million yuan and plans to list on the New Third Board on July 19, 2024 [3] - In 2024, the company expects to achieve a net profit of over 200 million yuan, with revenues of 1.138 billion yuan, and a net profit margin of 33.60% [6][7] - The company has a high customer concentration, with BYD being a major client, contributing 10.25% of total revenue in 2024 [9][10] - The IPO aims to raise 645 million yuan for four projects, including the construction of a new facility and R&D projects [12] Group 3: Zhejiang Yongli Precision Manufacturing Co., Ltd. - Zhejiang Yongli Precision focuses on the R&D, production, and sales of precision steel pipes and components for automotive applications, with a registered capital of 60 million yuan [14] - The company expects a net profit of 92.13 million yuan in 2024, with revenues projected at 568 million yuan [18][20] - The company has a high customer concentration, with BYD being the second-largest client in 2023 and 2024 [22][23] - The IPO plans to raise 380 million yuan for two projects, including the expansion of production capacity for chassis systems [26] Group 4: Zhejiang Haiseng Medical Device Co., Ltd. - Zhejiang Haiseng Medical specializes in the R&D, production, and sales of anesthesia and monitoring medical devices, with a registered capital of 64 million yuan [27] - The company anticipates a net profit of 68.04 million yuan in 2024, with revenues of approximately 304 million yuan [30][31] - The company has a low customer concentration, with the top five clients contributing only 21.66% of total revenue in 2024 [33] - The IPO aims to raise approximately 370.4 million yuan for three projects [34]